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Background: Memory impairment is a well-known effect of many 
benzodiazepine compounds which is mediated through their action on 
gamma-aminobutyric acid type A (GABAA) receptors. On the other hand, 
cannabinoids can affect learning and memory process through presynaptic 
modulation of the release of both excitatory glutamate and inhibitory GABA 
transmitters in brain regions involved in learning and memory. The aim of the 
present study was to investigate the effect of cannabinoids on memory 
impairment and long-term potentiation (LTP) reduction properties of the short 
acting benzodiazepine midazolam. 
Materials and Methods: One week after insertion of guide cannula by 
stereotaxic surgery, cannabinoid compounds or midazolam were administered 
by intracerebroventricular (i.c.v.) injection into lateral ventricle of male rats. 
Spatial memory task was evaluated using Morris water maze (MWM) test. 
Electrophysiological evaluation was done by field potential recording of 
hippocampal neurons in unconscious rats. 
Results: In MWM test, while i.c.v. administration of AM251 (200 and 500 
ng) per se could not change learning and memory function in rats, 
pretreatment of rats with AM251 (500 ng; i.c.v.) attenuated midazolam-
induced memory impairment. In field potential recording, while i.c.v. 
administration of AM251 (500 ng) and WIN55212-2 (10 µg) did not have any 
effect on population spike amplitude, pretreatment of rats with both AM251 
and WIN55212-2 significantly diminished midazolam-induced PS amplitude 
reduction in hippocampal neurons.  
Conclusion: Our 
Our results suggest the involvement of cannabinoid CB1 receptors in both 
memory impairment and LTP reduction in hippocampal neurons which was 
produced by midazolam. This interaction is likely through their effect on both 
GABAergic and glutamatergic receptors in hippocampus. 
Keywords: Midazolam, AM251, WIN55212-2, learning and memory, long-
term potentiation, Morris water maze 
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Introduction 
Gamma-aminobutyric acid type A (GABAA) 
receptors are a family of ligand-gated ion channels 
that are essential for the regulation of central 
nervous system function. Benzodiazepines (BDZs) 
act via non-selective target GABAA receptors. They 
have become one of the most widely groups of 
medications for the treatment of anxiety, insomnia, 
and epilepsy (1). Also, BDZs are used as 
intravenous anesthetic agents in which sedation and 
amnesic effects are exploited for clinical benefits 
(2). The short-term use of benzodiazepines 
adversely affects multiple areas of cognition, the 
most notable one being that it interferes with the 
formation and consolidation of memories of new 
material and may induce complete anterograde 
amnesia (3). Prior administration of an antagonist of 
BDZ sites reversed BDZ-induced amnesia (4). 
BDZ’s disruptive effect has been observed 
following administration either pre- or post- training 
in diverse learning and memory paradigms (5). Such 
an effect was also reported after both BDZ intra-
amygdala (6), and BDZ intra-dorsal hippocampus 
infusions (5). Midazolam (MDZ), a short-acting 
drug in the benzodiazepine class, is an anxiolytic 
sedative used in a variety of clinical settings (7). 
Consistent with other findings, it has been 
demonstrated that MDZ could affect fear memory 
reconsolidation (8). 
A great number of studies suggest an 
important role of the cannabinoid system in 
controlling the memory processes. High densities of 
CB1 receptors have been found in the hippocampus 
(9), a brain region that is essential for 
spatial/contextual learning in animals (10). 
Endocannabinoids (eCBs) are synthesized on 
demand at the post-synaptic sites of neurons after an 
increase in neural activity and calcium ion influx, 
and are then released into the synaptic cleft (11). 
Their main function appears to be the suppression of 
neurotransmitter release from presynaptic neurons 
(12). It has been shown that the cannabinoid 
agonists, WIN 55212-2, at some doses can impair 
memory function (13). Nonetheless, there is 
evidence that cannabinoid agonist can also enhance 
memory, depending on the route of administration, 
the dose used, the phase of memory and the level of 
emotional arousal at the time of training (14). 
The discovery of Wilson and Nicoll (15), 
Ohno-Shosaku et al. (16), and Kreitzer and Regehr 
(17) revealed a retrograde modulation of both 
excitatory and inhibitory neurotransmission by 
endocannabinoids. Later, it has been shown that 
exogenous cannabinoids can also attenuate both 
inhibitory (18) and excitatory (19) neurotransmitter 
release though action on presynaptic cannabinoid 
CB1 receptors in various brain region including the 
hippocampus.  
Interaction between cannabinoid compounds 
and GABA-mediated memory impairment has been 
studied by Alijanpour et al., in passive avoidance 
learning in mice. Pre-test intra-CA1 microinjection 
of AM251 prevented the ethanol response on 
ethanol-induced amnesia while pre-test intra-CA1 
microinjection of the same doses of AM251 had no 
effect on memory retrieval. These findings 
suggested the role of cannabinoid CB1 receptors of 
dorsal hippocampus in the effect of ethanol on 
passive avoidance learning (20). However, no study 
was performed on interaction between cannabinoids 
and BDZs in spatial learning and memory. The 
present study was performed to investigate the 
interaction between MDZ and the cannabinoid 
receptor agonist (WIN55212-2) and antagonist 
(AM251) on spatial memory and synaptic plasticity 
of hippocampal neurons. 
Methods 
Animals 
Adult male wistar rats weighting 270-300g 
(Pasture Institute, Tehran, Iran) were used in this 
study. Animals were housed three per cage in a room 
under a 12:12h light-dark cycle (lights on at 7:00 
a.m.) and controlled temperature (22±2C) with free 
access to food and tap water except in short time 
during experiments. Rats were randomly divided in 
ten groups of 5-6 animals and each animal was used 
only once. The experiments were performed between 
10:00 a.m. and 5:00 p.m. All procedures were in 
accordance with the National Institute of Health 
Guide for the Care and Use of Laboratory Animals 
(NIH Publications No. 80-23, revised 1996) and were 
approved by the local Research and Medical Ethics 
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The cannabinoid receptor agonist (WIN55212-
2) and antagonist (AM251) were purchased from 
Sigma-Aldrich (St. Louis, USA). MDZ was a gift 
from Tehran Chemie Pharmaceutical Co. (Tehran, 
Iran). The drugs were dissolved in DMSO (Sigma-
Aldrich; St Louis, USA) and injected at a constant 
volume of 2L/rat. The control group received 
vehicle (DMSO, 2L/rat). 
Surgery 
In order to evaluate the spatial memory of rats 
in Morris water maze test, the animals were 
anesthetized with intraperitoneal (IP) injection of 
anesthetic solution consisting of ketamine (85mg/kg) 
and xylazine (15mg/kg). Then, rats were placed in 
stereotaxic apparatus and implanted with guide 
cannula (8mm, 23-gauge) aimed at a site 1 mm above 
the right lateral ventricle according to following 
coordinates: 1 mm posterior and 1.6mm lateral to the 
bregma at a depth of 3.5 mm from the skull surface 
(21). Two jeweler screws were inserted into the skull 
and the cannula was fixed using dental cement. Then 
the cannula was closed with a stylet.  
Morris water maze (MWM) test 
The water maze was a dark circle pool (a tank 
made of galvanized metal, 155 cm diameter, 60cm 
depth) that was filled to a depth of 25cm with 22±1C 
water. A clear Plexiglas platform (diameter 10 cm) 
was submerged 1.5cm below the surface of the water 
and located in the center of the arbitrary designed 
northeast (NE), southeast (SE), southwest (SW) and 
northwest (NW) orthogonal quadrants.  
Behavioral training 
One week after surgery, the cannula stylet was 
removed and injection needle (30-gauge) connected to 
a short piece of polyethylene tubing and a 5µl 
Hamilton syringe was inserted into right lateral 
ventricle of the conscious rat. Then 2µl of each drug 
or its vehicle was injected slowly over 2-3 min.  In 
each experimental group, WIN55212-2 at the doses of 
500ng and 10g, AM251 at the doses of 200ng and 
500ng or their vehicles were injected 5 min before 
administration of MDZ (500ng) or its vehicle. The 
rats were free to move in their cage during drug 
administration. Five min. after last drug injection, 
animals were subjected to training sessions. Each 
animal was trained during eight trials divided into two 
even blocks with 5 min interval between each block. 
For each trial, the rats were gently released into the 
pool, facing the wall. Four different releasing points 
(NE, SE, SW, and NW) were randomly selected. Rats 
were given a maximum of 60 s. to find the platform. 
After finding the platform, the rats were allowed to 
remain for 20 s., and were then placed in a cage for 30 
s. until the start of the next trial. Animals failing to 
find the platform in 60 s. were gently placed on the 
platform and were allowed to rest for 20 s. At the end 
of the training sessions, the animals were returned to 
their home cages. Twenty-four hours later, the 
animals were subjected to retention test (probe test) 
consisted of a 60 s. swimming in tank without the 
presence of the platform. In order to assess the effect 
of drugs on rat locomotion, the velocity of swimming 
was measured during training sessions. In addition, 
the possibility of drug interference with animal vision, 
after probe test, rats were subjected to a 60 s. trial to 
find and climb the visible platform. 
Electrophysiological procedure 
Rats were anesthetized by intraperitoneal 
injection of 1.5g/kg urethane and placed in a 
stereotaxic device. Supplementary injections of 
urethane (0.2–0.5 g/kg) were given when necessary to 
ensure full anesthesia. A heating pad was used to 
maintain the temperature of the animals at 
36.5±0.5°C. The skin was removed from the skull and 
small holes were drilled in the skull at the positions of 
the guide cannula as well as stimulating and recording 
electrodes. The guide cannula was placed into lateral 
ventricle according to coordination previously 
mentioned in behavioral procedure. Then, the bipolar 
stainless steel recording and stimulating electrodes 
(0.125 mm diameter, Advent, UK) were positioned in 
the granular cells of dentate gyrus (AP = -3.8; ML = 
2.3; DV = 2.7–3.2 mm from the skull surface) and 
perforant pathway (AP = −8.1; ML = 4.3; DV = 3.2 
mm from the skull surface), respectively according to 
the atlas of Paxinos and Watson (21). In order to 
minimize trauma to brain tissue, the electrodes were 
lowered very slowly (0.2 mm/min) from cortex to the 
hippocampus. Correct electrode depths were 
determined by optimizing the evoked response. The 
test stimuli were delivered at 0.1 Hz (22) to the 
perforant pathway every 10 s. with constant current 
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stimuli. Stimulation intensity was adjusted to elicit a 
maximal field population spike (PS) and field 
excitatory postsynaptic potential (fEPSP). The PS 
amplitude was measured as the difference in voltage 
between the peak of the first positive wave and the 
peak of the first negative deflection and the fEPSP 
slope was measured as the maximum slope between 
initial point of EPSP and the first positive wave in 
order to measure synaptic efficacy. PS and fEPSPs 
were evoked in the dentate gyrus region using 0.1 Hz 
stimulation. Baseline recordings were taken at least 
30 min. and after ensuring a steady state baseline 
response. Then drugs were administered by 
intracerebroventricular (i.c.v.) injection through the 
guide cannula. In each experimental group, AM251, 
WIN 55212-2 or their vehicle were injected 5 min 
before administration of MDZ or its vehicle. The 
doses and the volume of injection were similar to 
those explained in behavioral experiment. Five min. 
after drugs administration, the LTP was induced using 
a high-frequency stimuli protocol of 200 Hz (10 
bursts of 15 stimuli, 0.2 ms stimulus duration, 10 s. 
inter-burst interval) at a stimulus intensity that evoked 
a PS amplitude and fEPSP slope of approximately 
80% of maximum response. All potentials employed 
as baseline and also after high frequency stimuli were 
evoked at a stimulus intensity which produced 40% of 
this maximum. Both fEPSP and PS were recorded 
each 5 min. for the periods of 60 min. after the high 
frequency stimuli in order to determine any changes 
in the synaptic response of dentate gyrus neurons. For 
each time-point, 10 consecutive evoked responses 
were averaged at 10 s. stimulus interval (23). 
Verification of cannula position 
After termination of the behavioral tests, the 
rats were anesthetized and intra-cardially perfused 
with paraformaldehide (%4) and their brains were 
removed. Coronal sections with 200 m thicknesses 
were provided using vibratome and injected locations 
were examined under a stereomicroscope. Only 
results obtained from animals in which tips of the 
injection needles were correct were considered 
(Figure 1). Same method was used after 
elctrophysiological recording for injection site 
verification.  
Statistical analysis 
The results are shown as mean±SEM. The 
results of MWM test as well as the results of 
electrophysiological recordings were evaluated using 
two-way ANOVA followed by Bonferroni’s post-test, 
considering time as a factor and treatment as the other 
factor. Also, in order to evaluate the overall drug-
induced changes during recording time, the area under 
the curve (AUC) of potential vs. time was calculated. 
Data of AUC were then analyzed using one-way 
ANOVA followed by Dunnett's multiple comparison 
tests. Statistical analysis was performed using 
Graphpad Prism software (Version 5; Graphpad Inc.). 
The p value of less than 0.05 was considered as 
statistically significant. 
Results 
Training sessions in MWM test – changes in 
distance to platform 
The results were shown in figure 2. One-way 
ANOVA revealed a significant difference between 
groups [F(7,63)=6.341, p<0.0001; Figure 2A]. 
Further analysis by Dunnett’s test showed a 
significant increase in group treated with MDZ 
(500ng; p<0.001) compared to control group. This 
effect of MDZ was attenuated by co-administration 
with AM251 (500ng), but not AM251 (200ng). 
Furthermore, treatment of rats with WIN55212-2 
(10ug) significantly increased distance to platform 
compared to control group (p<0.01). However, co-
administration of WIN55212-2 (10ug) and MDZ 
(500ng) did not alter the effect of each drug per se. 
 
Fig. 1.  A typical photo micrograph of a coronal 
section through the injection site (arrow) in the 
lateral ventricle. The tip of the guide cannula can be 
seen on the right side. 
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Training sessions in MWM test – changes in 
escape latency 
One-way ANOVA revealed significant change 
between groups [F(7,65)]=4.131, p=0.0008; Figure 
2B]. Further analysis showed a significant increase in 
escape latency in group treated with MDZ (500ng; 
p<0.01).The effect of MDZ was attenuated by co-
administration AM251 (500ng), but not AM251 
(200ng). Moreover, treatment of rats with WIN55212-
2 (10ug) significantly increased escape latency 
compared to control group (p<0.05). Co-
administration of WIN55212-2 (10ug) and MDZ 
(500ng) did not alter the effect of each drug per se. 
 
Training sessions in MWM test – changes in 
swimming velocity 
In order to evaluate the effect of drugs on 
animal locomotion, the velocity of swimming was 
compared between groups. One-way ANOVA 
revealed no significant change in swimming velocity 
between groups [F(7,63)=0.2102, p=0.9818; Figure 
2C]. 
Probe test 
The results were shown in Figure 3. One-way 
 
Fig. 2.  The effect of i.c.v. administration of 
WIN55212-2, AM251 or their vehicle 5 min before 
i.c.v. administration of MDZ (MDZ) or its vehicle 
on learning of rats in MWM test. Rats were 
subjected to 8 training sessions 5 min after last 
drug injection. The mean distance of swimming 
from the platform (A), the mean time of swimming 
to find the platform (i.e. escape latency; B) and the 
mean velocity of swimming (c) during eight 
training sessions were depicted. Values are mean± 
SEM of 5-6 rats. 
*p<0.05, **p<0.01, ***p<0.001 compared to 
control (vehicle) group. 
 
Fig. 3.  The effect of i.c.v. administration of 
AM251, WIN55212-2 or their vehicles 5 min 
before i.c.v. administration of MDZ (MDZ) or its 
vehicle on memory of rats in MWM test. Rats were 
subjected to probe test 24h after last training 
session. The time spent in target quadrant (A), and 
the number of entrance into target quadrant (B) 
during probe test were depicted. Values are mean± 
SEM of 5-6 rats. 
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ANOVA revealed no significant difference in time 
spent in target zone [F(7,63)=2.053, p=0.062; Figure 
3A]. Moreover, there was no significant difference in 
frequency of entrance into target zone between 
control and treated groups [F(7,63)=1.028, p=0.042; 
Figure 3B]. 
Visual test 
All of the animals were able to find the visible 
platform during 60s. time of visual test (data not 
shown). 
Field potential recording 
The results were shown in figure 4. Two-way 
ANOVA revealed a significant effect of treatment 
[F(5,304)=33.21, p<0.0001; Figure 4A] and time 
[F(18,304)=3.192, p<0.0001; Figure 4A] on LTP 
population spikes. Further analysis by Bonferroni’s 
post-test revealed a significant decrease in population 
spikes at various time courses after HFS application 
in MDZ-treated group, WIN55212-2-treated group, 
and the group received co-administration of 
WIN55212-2 and MDZ compared to control group. 
Moreover, comparison of AUC of the LTP population 
spikes using one-way ANOVA revealed significant 
difference between treated groups [F(5,16)=3.113, 
p=0.038; Figure 4B]. Post hoc analysis using 
Dunnett’s test showed a significant decrease in MDZ-
treated group (p<0.05) compared to control group. 
For EPSP slope of LTP, two-way ANOVA 
revealed significant effect of treatment 
[F(5,285)=17.70, p<0.0001; Figure 4C] and time 
[F(18,285)=2.816, p=0.0002; Figure 4C]. However, 
further analysis using Bonferroni’s post-test revealed 
no significant change in treated groups compared to 
control group. Moreover, comparison of the AUC of 
 
Fig. 4.  Left: The effects of i.c.v. administration of AM251, WIN55212-2 or their vehicles, 5 min before i.c.v. 
administration of MDZ (MDZ) or its vehicle on high frequency stimulation (HFS)-induced LTP in the dentate 
gyrus of hippocampus in rats. The population spike (top) and EPSP slope (bottom) were measured every 5 min 
from 30 min before until 60 min after HFS induction. Data are plotted as the average percentage change from 
baseline responses. Values are %mean±S.E.M. Middle) Area under the curve of plots depicted on left panel. 
Right: Sample traces representing the effect of drug administration on fEPSP and PS before and after LTP 
induction (average of 5 responses)  
*p<0.05, **p<0.01, ***p<0.001 compared to control (vehicle) group (N= 5 for each group). 
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EPSP slope of LTP using one-way ANOVA revealed 
no significant change in treated groups [F(5,15)=2.48, 
p=0.08; Figure 4D]. 
Discussion 
The results of this study showed that CB1 
receptor is important in amnesic effect of MDZ. 
Administration of MDZ into lateral ventricle, 
impaired learning of rats compared to the control 
group. Administration of AM251 (either 200ng or 500 
ng) alone did not affect learning and memory in rats. 
Previous studies showed that microinjection of both 
WIN55212-2 (5g/side) and AM251 (6ng/side) 
impaired not only spatial learning in water maze test 
but also the LTP in the Schaffer collateral-CA1 
projection (24). 
Co-administration of AM251 (200ng) did not 
change MDZ effects on learning, but co-
administration of AM251 (500ng) and MDZ 
diminished MDZ-induced learning impairment. 
Administration of WIN55212-2 (10g) per se 
impaired spatial learning and memory of rats, which 
is consistent with the results of previous studies 
showing memory impairment following intra-
hippocampal administration of WIN55212-2 at the 
doses of 500ng in a step-down type inhibitory 
avoidance task (25, 26). Also, microinjection of 
WIN55212-2 into basolateral amygdala impaired both 
fear acquisition and consolidation, but not retrieval in 
the aversive contextual fear task (27). In our study, 
co-administration of WIN55212-2 (10g) and MDZ, 
however, did not change MDZ effect on learning of 
the rats. These effects seems to be mnemonic since 
the drugs showed no impairment on motor 
performance which was evaluated by measurement of 
swim velocity. 
In electrophysiological study, i.c.v. 
administration of MDZ 5 min. before high frequency 
stimulation significantly reduced PS amplitude which 
could be considered as prevention of LTP induction. 
On the other hand, while administration of AM251 
(500ng) produced no effect on fEPSP nor on PS 
amplitude per se, however, it could diminish MDZ-
induced LTP impairment when administered before 
i.c.v. administration of MDZ. It is well established 
that agonists at the benzodiazepine site show 
anxiolytic and amnesic properties whereas inverse 
agonists, such as β-carbolines, exert anxiogenic and 
learning-enhancing actions (28). MDZ is an 
anxiolytic and sedative agent which is used in a 
variety of clinical settings. MDZ-induced amnesia is 
through facilitating the action of GABA on 
postsynaptic neurons. Furthermore, BDZs are known 
to reduce LTP in the hippocampus. It has been 
demonstrated that diazepam can reduce hippocampal 
LTP in Schaffer collateral-CA1, mossy fiber-CA3 and 
perforant path-dentate gyrus synapses (29). Also, it 
has been shown that MDZ had little influence on 
baseline synaptic responses but was very effective in 
blocking LTP through modulation of GABAA 
receptors (30). Same results were also obtained in our 
study in which MDZ did not alter the baseline 
synaptic function while LTP induction was 
significantly reduced. 
Many studies have demonstrated that 
cannabinoids impairs learning and memory processes 
(31, 32). However there are some controversies about 
the involvement of CB1 antagonists in behavioral 
memory tests and LTP induction. Administration of 
the cannabinoid CB1 receptor antagonist did not 
produce significant effect upon memory of mice in 
inhibitory avoidance task (33) nor in high frequency 
stimulation-induced LTP induction (34, 35). In 
contrast, Carlson et al. (36) and de Oliveira Alvares et 
al. (37) have found that a CB1 receptor antagonist 
inhibits LTP induction in hippocampal CA1 neurons. 
In our study, no effect was observed after i.c.v. 
administration of AM251 per se on LTP-induction in 
hippocampal neurons. Moreover, our results also 
showed that AM251 per se also had no effects on 
spatial learning of rats in MWM task. On the other 
hand, administration of WIN55212-2 (10g) either 
alone or in combination with MDZ significantly 
reduced PS-amplitude at some time points after HFS 
induction, though the overall change in PS-amplitude, 
which was shown by the area under the curve, did not 
changed significantly between WIN55212-2-treated 
and control group. 
A high density of GABAA receptors exists in 
brain areas which are important in learning and 
memory process, such as the hippocampus (38). 
There is few evidence regarding interaction between 
the cannabinoid CB1 receptor and the GABAergic 
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system in learning and memory process (39). In this 
study, we suggested the possible involvement of the 
cannabinoid CB1 receptor in the amnesic action of 
MDZ in MWM task as well as its effect on plasticity 
of hippocampal neurons. The BDZs produce their 
clinical effects by acting on GABAA receptors. The 
activation of the GABAA receptors results in neuronal 
hyperpolarization via the opening of chloride-
permeable ion channels. High levels of CB1 receptors 
are expressed in both GABAergic and glutamatergic 
neurons in the hippocampus. The activation of the 
cannabinoid CB1 receptor in this region decreases 
both inhibitory GABAergic and excitatory 
glutamatergic neurotransmission via presynaptic 
inhibition of neurotransmitter release (40).  
The finding that the blockade of cannabinoid 
CB1 receptor by AM251 counteracts the action of 
MDZ both in the behavioral and electrophysiological 
tests supports the key role of these receptors in the 
action of BDZs. Consistent with our findings, García-
Gutiérrez et al. showed that CB1 receptors are 
involved in alprazolam-induced amnesia (39).  
Although the activation of cannabinoid 
receptor could suppress the release of both glutamate 
and GABA in hippocampal neurons, however, in this 
study, it seems that the effects of CB1 agonist and 
antagonist were primarily through CB1 receptors 
located at glutamatergic synapses. In this regard, the 
CB1 antagonist AM251 could primarily inhibit CB1 
receptors at glutamatergic synapses, results in 
increase of glutamate release and physiologically 
attenuation of GABA-mediated effects of MDZ. 
Likewise, WIN55212-2 primarily activates CB1 
receptors at glutamatergic synapses and inhibition of 
glutamate release could physiologically enhance 
MDZ effect. 
Conclusion 
Our results showed an inhibitory effect of 
AM251 on MDZ-induced both learning and memory 
impairment and reduction in LTP formation. On the 
other hand, no enhancement of MDZ effect was 
observed when co-administered with WIN55212-2 
neither on learning and memory nor on LTP 
formation. Our results suggest that the effects of 
cannabinoid compounds, at least at the doses used in 
this study, were through their effects on glutamatergic 
system, but not through their action on GABAergic 
system which is basically is modulated by BDZs such 
as MDZ. 
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